| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905
Ventricular concentrations of atrial, brain (BNP) and C-type natriuretic peptide are enhanced in congestive heart failure (CHF). Natriuretic peptide receptors are present on ventricular myocytes and stimulate guanosine 3',5'-cyclic monophosphate (cGMP) production. cGMP has been demonstrated to affect myocyte function in vitro. Thus we hypothesized that the intracardiac natriuretic peptide system may modulate myocardial and coronary function in CHF. To test this hypothesis, the effects of an intracoronary infusion of the natriuretic peptide receptor antagonist HS-142-1 on ventricular and coronary function were examined in anesthetized dogs with chronic CHF. To determine whether receptor stimulation had contrasting effects to those of receptor blockade, intracoronary BNP was infused in anesthetized normal and CHF dogs. Low-dose HS-142-1 delayed and slowed left ventricular (LV) relaxation and decreased coronary blood flow without changes in LV pressures. Higher doses further impaired LV relaxation without further decreases in coronary blood flow. In normal and CHF dogs, exogenous BNP produced the opposite effect with a quicker onset and faster rate of LV relaxation without effects on LV pressures or coronary blood flow. The endogenous natriuretic peptide system has an autocrine-paracrine role to modulate LV and coronary vascular function in CHF.
ventricular function; coronary circulation; guanosine 3',5'-cyclic monophosphate; heart failure
This article has been cited by other articles:
|
|
 |
|
  J. B. Patel, M. L. Valencik, A. M. Pritchett, J. C. Burnett Jr., J. A. McDonald, and M. M. Redfield Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H777 - H784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Chen, J. H. Traverse, M. Hou, Y. Li, R. Du, and R. J. Bache Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1513 - H1520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. D'Souza, D. M. Yellon, C. Martin, R. Schulz, G. Heusch, A. Onody, P. Ferdinandy, and G. F. Baxter B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1592 - H1600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Lainchbury, O. Lisy, J. C. Burnett Jr., D. M. Meyer, and M. M. Redfield Actions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2002; 282(4): R993 - R998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Y. T. Hart, E. L. Hahn, D. M. Meyer, J. C. Burnett Jr., and M. M. Redfield Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H146 - H154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gyurko, P. Kuhlencordt, M. C. Fishman, and P. L. Huang Modulation of mouse cardiac function in vivo by eNOS and ANP Am J Physiol Heart Circ Physiol, March 1, 2000; 278(3): H971 - H981. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Lainchbury, J. C. Burnett Jr., D. Meyer, and M. M. Redfield Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs Am J Physiol Heart Circ Physiol, January 1, 2000; 278(1): H33 - H40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Masciotra, S. Picard, and C. F. Deschepper Cosegregation Analysis in Genetic Crosses Suggests a Protective Role for Atrial Natriuretic Factor Against Ventricular Hypertrophy Circ. Res., June 25, 1999; 84(12): 1453 - 1458. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Dzeja, K. T. Vitkevicius, M. M. Redfield, J. C. Burnett, and A. Terzic Adenylate Kinase–Catalyzed Phosphotransfer in the Myocardium : Increased Contribution in Heart Failure Circ. Res., May 28, 1999; 84(10): 1137 - 1143. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. WILLENBROCK, I. PAGEL, M. SCHEUERMANN, K. HÖHNEL, H. S. MACKENZIE, B. M. BRENNER, and R. DIETZ Renal Function in High-Output Heart Failure in Rats: Role ofEndogenous Natriuretic Peptides J. Am. Soc. Nephrol., March 1, 1999; 10(3): 572 - 580. [Abstract] [Full Text]
|
|
|
|
|
|
C. Zellner, A. A. Protter, E. Ko, M. R. Pothireddy, T. DeMarco, S. J. Hutchison, T. M. Chou, K. Chatterjee, and K. Sudhir Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries Am J Physiol Heart Circ Physiol, March 1, 1999; 276(3): H1049 - H1057. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Chen, J. G. Lainchbury, G. J. Harty, and J. C. Burnett Jr Maximizing the Natriuretic Peptide System in Experimental Heart Failure: Subcutaneous Brain Natriuretic Peptide and Acute Vasopeptidase Inhibition Circulation, February 26, 2002; 105(8): 999 - 1003. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
